New Zealand’s Medsafe retains classification of low-dose CBD

The Medicines and Medical Devices Safety Authority (Medsafe) has recommended New Zealand keep its current regulatory classification of low dose cannabidiol (CBD), setting the country up to diverge from the position of its neighbor Australia.   At its latest meeting, Medsafe’s Medicines Classification Committee looked at the regulatory status of CBD, following the down-scheduling of […]


Go to Source

Powered by WPeMatico